Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336675 | 0.93 | ALDH1A1 (0.36) | MAPTL3MBTL1GAAALDH1A1TRPA1 | |
| SCHEMBL21009822 | 0.82 | L3MBTL1 (0.44) | L3MBTL1GAAALDH1A1TRPA1NPSR1 | |
| SCHEMBL381187 | 0.82 | L3MBTL1 (0.44) | L3MBTL1GAAALDH1A1TRPA1NPSR1 | |
| SCHEMBL29597879 | 0.78 | MAPT (0.39) | MAPTL3MBTL1GAAALDH1A1NPSR1 | |
| SCHEMBL31547138 | 0.74 | ALDH1A1 (0.45) | L3MBTL1ALDH1A1NPSR1TSHR | |
| SCHEMBL28249755 | 0.74 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1TRPA1NPSR1TSHR | |
| SCHEMBL17200481 | 0.74 | ALDH1A1 (0.45) | L3MBTL1ALDH1A1NPSR1TSHR | |
| SCHEMBL20833769 | 0.74 | CHRNB2 (0.39) | MAPTL3MBTL1GAAALDH1A1NPSR1 | |
| SCHEMBL197612 | 0.73 | ALDH1A1 (0.48) | L3MBTL1GAAALDH1A1NPSR1TSHR | |
| SCHEMBL198506 | 0.73 | ALDH1A1 (0.48) | L3MBTL1GAAALDH1A1NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424860-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | MSD K.K. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120028970-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2010126163-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-11-04 | — | — | WO | disclosed |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
| US-6960601-B2 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2005099705-A2 | PREPARATION OF IMIDAZOLE DERIVATIVES AND METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1432691-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| WO-2003040107-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | MAPT 3231/4885L3MBTL1 3403/4885GAA 704/4885 |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | MAPT 3231/4885L3MBTL1 3403/4885GAA 704/4885 |
| US-20120028970-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | AR, NR5A1, ARL1 | MAPT 1577/4885L3MBTL1 2834/4885GAA 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.